Praxbind 50 mL Solution for infusion
PDF Leaflet Revision Date: 23 May 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Reversal of dabigatran anticoagulant effects in emergencies.
Dosage (summary)
5 g (2 vials of 2.5 g) IV; may repeat if needed.
Onset of Action / Duration
Onset: Immediate, Duration: Up to 24 hours
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety not established in pregnancy and lactation.
Key Drug Interactions
- No significant interactions with other anticoagulants
Common side effects
- Transient proteinuria
- Hypersensitivity reactions
Counselling Points
- Monitor for bleeding
- Record trade name and batch number
- Consider resuming anticoagulant therapy after stabilization
Serious warnings
- Risk of thromboembolic events after reversal
Important Disclaimer
The Praxbind 50 mL Solution for infusion professional information leaflet below is the property of Ingelheim Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
